Cargando…

Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole

Chagas' Disease, caused by the protozoan parasite Trypanosoma cruzi, is responsible for up to 41% of the heart failures in endemic areas in South America and is an emerging infection in regions of North America, Europe, and Asia. Treatment is suboptimal due to two factors. First, the lack of an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calvet, Claudia Magalhães, Silva, Tatiana Araújo, Thomas, Diane, Suzuki, Brian, Hirata, Ken, Siqueira-Neto, Jair Lage, McKerrow, James H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561097/ https://www.ncbi.nlm.nih.gov/pubmed/32970692 http://dx.doi.org/10.1371/journal.pntd.0008726

Ejemplares similares

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
por: Aguilera, Elena, et al.
Publicado: (2018)

Sensibilidad in vitro a benznidazol, nifurtimox y posaconazol de cepas de Trypanosoma cruzi de Paraguay
por: Acosta, Nidia, et al.
Publicado: (2020)

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection
por: Calvet, Claudia Magalhaes, et al.
Publicado: (2017)

Molecular dissection of Chagas induced cardiomyopathy reveals central disease associated and druggable signaling pathways
por: Wozniak, Jacob M., et al.
Publicado: (2020)

Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease
por: Assíria Fontes Martins, Tassiane, et al.
Publicado: (2015)

Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2013)

Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display
por: Rodriguez Carnero, Luis Antonio, et al.
Publicado: (2023)

Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant Trypanosoma cruzi parasites treated with benznidazole
por: Téllez, Jair, et al.
Publicado: (2019)

Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51
por: Vieira, Debora F., et al.
Publicado: (2014)

High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi
por: Bernatchez, Jean A., et al.
Publicado: (2020)

Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas
por: Echeverría, Luis Eduardo, et al.
Publicado: (2020)

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery
por: Ekins, Sean, et al.
Publicado: (2015)

4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency
por: Calvet, Claudia M., et al.
Publicado: (2014)

Identification of Leucinostatins from Ophiocordyceps sp. as Antiparasitic Agents against Trypanosoma cruzi
por: Bernatchez, Jean A., et al.
Publicado: (2022)

Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics
por: Trochine, Andrea, et al.
Publicado: (2014)

Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations
por: Lima, Davi Alvarenga, et al.
Publicado: (2023)

Chagas Cardiomyopathy Manifestations and Trypanosoma cruzi Genotypes Circulating in Chronic Chagasic Patients
por: Ramírez, Juan David, et al.
Publicado: (2010)

Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease
por: de Oliveira-Silva, Jaquelline Carla Valamiel, et al.
Publicado: (2015)

Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in Trypanosoma cruzi-infected cardiac cells
por: Barbosa, Juliana Magalhães Chaves, et al.
Publicado: (2022)

Effect of benznidazole on cerebral microcirculation during acute Trypanosoma cruzi infection in mice
por: Gonzaga, Beatriz Matheus Souza, et al.
Publicado: (2022)

Combined Treatment of Heterocyclic Analogues and Benznidazole upon Trypanosoma cruzi In Vivo
por: Batista, Denise da Gama Jaén, et al.
Publicado: (2011)

Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection
por: Li, Xiaomo, et al.
Publicado: (2021)

Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
por: Fonseca, Kátia da Silva, et al.
Publicado: (2021)

Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection
por: Engel, Juan C., et al.
Publicado: (1998)

Combination With Tomatidine Improves the Potency of Posaconazole Against Trypanosoma cruzi
por: Rocha-Hasler, Marianne, et al.
Publicado: (2021)

A novel ABCG-like transporter of Trypanosoma cruzi is involved in natural resistance to benznidazole
por: Zingales, Bianca, et al.
Publicado: (2015)

Benznidazole-resistance in Trypanosoma cruzi: Evidence that distinct mechanisms can act in concert()
por: Campos, Mônica C.O., et al.
Publicado: (2014)

Miltefosine and Benznidazole Combination Improve Anti-Trypanosoma cruzi In Vitro and In Vivo Efficacy
por: Gulin, Julián Ernesto Nicolás, et al.
Publicado: (2022)

Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection
por: Barbosa, Juliana Magalhães Chaves, et al.
Publicado: (2022)

The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion
por: Doyle, Patricia S., et al.
Publicado: (2011)

Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4(+)CD8(+) T cells in chronic Chagas disease patients
por: Pérez-Antón, Elena, et al.
Publicado: (2018)

Molecular characterization of the hexose transporter gene in benznidazole resistant and susceptible populations of Trypanosoma cruzi
por: dos Santos, Paula F, et al.
Publicado: (2012)

Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi
por: Puente, Vanesa, et al.
Publicado: (2018)

Spatial metabolomics identifies localized chemical changes in heart tissue during chronic cardiac Chagas Disease
por: Dean, Danya A., et al.
Publicado: (2021)

Antiparasitic Activity of Hippeastrum Species and Synergistic Interaction between Montanine and Benznidazole against Trypanosoma cruzi
por: Piñeiro, Mauricio, et al.
Publicado: (2023)

Trypanosoma cruzi infection associated with atypical clinical manifestation during the acute phase of the Chagas disease
por: Rangel-Gamboa, Lucia, et al.
Publicado: (2019)

Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51
por: Gunatilleke, Shamila S., et al.
Publicado: (2012)

Meiotic sex in Chagas disease parasite Trypanosoma cruzi
por: Schwabl, Philipp, et al.
Publicado: (2019)

Peeking into the mysterious world of Trypanosoma cruzi and Chagas disease
por: Macedo, Andréa M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h42jnh8nb16h0e25ul6rk1u1lp